ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
After FDA rebuff, Celgene on track to refile ozanimod—in 2019
fiercebiotech
May 07, 2018Celgene suffered an embarrassing setback in February when it got a refuse-to-file letter for its multiple sclerosis drug ozanimod. Now, the company says, it expects to resubmit the NDA in the first quarter of 2019, delaying its timeline by a year.
Pharma Sources Insight January 2025
